Sunshine Biopharma Inc. (SBFM) - What You Need to Know

Thinking about investing in Sunshine Biopharma? Biotech stocks can feel like a foreign language. Let’s break down their May 18, 2026 stock sale in plain English over a quick coffee.

1. What does this company actually do?

Sunshine Biopharma has two distinct business areas:

• The "Dream Big" Science Side: They are developing new drugs, including an mRNA treatment for liver cancer and an antiviral for COVID-19. Drug development is highly risky and expensive. This side makes zero money right now and only spends cash.
• The "Everyday Business" Side: To fund their research, they own Nora Pharma. Nora sells 60 generic prescription drugs in Canada to bring in steady sales. This helps pay the bills, but the generic drug market has very low profit margins.

2. What is this new stock offering?

On May 18, 2026, Sunshine is raising money by selling "units" to the public.

• The Price: They are selling 12 million units for $0.50 each to raise $6 million before fees.
• What’s in a "Unit"? For $0.50, you get one share of stock and two "Series C Warrants." Think of warrants as coupons. They let you buy more shares for $0.50 anytime over the next five years. Big investors might get "pre-funded" warrants instead of shares to avoid owning too much of the company at once.
• The Catch: You cannot trade these coupons on any stock exchange, making them very hard to sell. Also, their investment bank, Aegis Capital, is working on a "best efforts" basis. They do not promise to buy any unsold stock. If buyers do not step up, Sunshine might not get the full $6 million.

3. What will they do with the money?

They plan to use the cash for "general corporate purposes." The company didn't provide a lot of specific details about this in their filing, but in plain English, they need this money to keep the lights on. The cash will likely go toward paying salaries, buying inventory for Nora Pharma, and funding basic lab work. Without this cash injection, they could run out of money quickly.

4. What are the biggest risks?

Biotech investing is a roller coaster, and Sunshine has major warning signs:

• Massive Ownership Shrinkage (Dilution): Sunshine only has 5 million shares today. Selling 12 million new units is a huge jump. Worse, the new coupons can create 48 million more shares. Even past investors had their coupon prices slashed to $0.50 because of this cheap sale. If everyone uses their coupons, the share count could explode to 80 million. This would shrink your ownership slice to a tiny sliver.
• Kicked Off Nasdaq: Nasdaq requires stocks to stay above $1.00. Because Sunshine trades below this, they face delisting. If they move to the "Pink Sheets" market, buying and selling the stock will become incredibly difficult.
• The CEO Rules: CEO Dr. Steve N. Slilaty controls 130 million votes through special preferred shares. Regular investors have virtually zero voting power. You cannot influence any company decisions.
• The Cash Burn: Sunshine has lost over $76 million since starting. They have asked investors for cash six times since 2022. They have $6.9 million left, but they burn through it fast and will likely need to sell more shares soon.

The Bottom Line: Sunshine Biopharma is a high-risk penny stock. You are betting their Canadian drug business can support them while they chase a cancer cure. Because of massive ownership shrinkage, heavy institutional advantages, and absolute CEO control, only invest money you can afford to lose.